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Upregulation of Tenascin-C Expression by IL-13 in
Human Dermal Fibroblasts via the Phosphoinositide
3-kinase/Akt and the Protein Kinase C Signaling
Pathways
Masatoshi Jinnin1, Hironobu Ihn2, Yoshihide Asano1, Kenichi Yamane1, Maria Trojanowska3
and Kunihiko Tamaki1
In this study, we examined the genes targeted by IL-13 in human dermal fibroblasts using a cDNA microarray.
We focused on the tenascin-C (TN-C) gene, which was identified as one of the genes induced by IL-13. IL-13
induced transcriptional activity of TN-C. IL-13-mediated TN-C expression was inhibited by treatment with
wortmannin or LY294002, or Calphostin C. IL-13 induced the phosphorylation of the phosphoinositide 3-kinase
(PI3K) regulatory subunit p85, induced tyrosine phosphorylation of Akt, upregulated Akt kinase activity, and
activated protein kinase C (PKC)-d and -e. The IL-13-induced increase in TN-C protein expression was abrogated
by the transfection of a dominant-negative mutant of Akt, PKC-d, or PKC-e. In conclusion, we showed that the
PI3K/Akt and/or PKC signaling pathways are essential for the IL-13-mediated increase in TN-C. Both serum levels
of IL-13 and the expression levels of TN-C in the dermis are increased in patients with systemic sclerosis. Our
findings suggest that the expression of TN-C is upregulated in this disease due to IL-13 signaling, and that a
blockade of the PI3K or PKC signaling pathway may also have therapeutic value by reducing the amount of TN-C
produced during fibrosis.
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INTRODUCTION
IL-13 is a lymphokine of 112 amino acids with a molecular
mass of 12.5 kDa produced by activated Type 2 helper cells
(Minty et al., 1993). The gene for IL-13 is closely linked to the
IL-4 gene (Morgan et al., 1992), and IL-13 protein has been
shown to have a 30% identity in amino-acid sequence with
IL-4 protein (Zurawski et al., 1993). In addition, the receptor
for IL-4 and that for IL-13 may share a common component
that appears to function in signal transduction (Zurawski
et al., 1993).
Sharing many biological properties with IL-4 as a
pleiotropic immune regulatory cytokine, IL-13 induces
changes in the cell surface phenotype and has immunomo-
dulatory effects on B cells and human monocytes (McKenzie
et al., 1993; Zurawski and de Vries, 1994). In sharp contrast
to IL-4, IL-13 has been shown not to affect resting or activated
T cells (Punnonen et al., 1993; Zurawski and de Vries, 1994).
On the other hand, there have been quite a few reports
that discussed the effects of Il-13 on dermal fibroblasts.
High-affinity IL-13 receptors are reported to be expressed in
normal skin fibroblasts (Yoshidome et al., 1999). The
expression of total collagen and a1(III) procollagen is
upregulated in normal skin fibroblasts after stimulation by
IL-13 (Oriente et al., 2000). Moreover, IL-13 inhibits
production of IL-1b-induced matrix metalloproteinase-1 and
-3 and enhances production of tissue inhibitor of metallo-
proteinase-1 by dermal fibroblasts (Oriente et al., 2000).
Thus, in the skin, IL-13 is thought to be associated with the
regulation of extracellular matrix synthesis and tissue
remodeling.
In this study, we identified the target genes of IL-13 in
human dermal fibroblasts using a cDNA microarray. We then
focused on the tenascin-C (TN-C) gene, which was identified
as one of the genes induced by IL-13 in the microarray
analysis. We clarified the mechanisms by which TN-C
expression is regulated by IL-13 in dermal fibroblasts,
because both IL-13 and TN-C are implicated in fibrotic
disorders.
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RESULTS
Effects of IL-13 on gene expression profiles as measured with
the cDNA microarray
The technique of differential hybridization of cDNA expres-
sion arrays was used to identify differences in the expression
pattern of genes between control and IL-13-treated fibro-
blasts. Among nearly 630 genes, over 300 showed no
significant hybridization signal in either control or IL-13-
treated cultures. Results for important genes are shown in
Table 1. The expression of extracellular matrix-related genes
or cancer-related genes as well as immune-related genes was
upregulated by IL-13. TN-C expression increased significantly
Table 1. Summary of Il-13-regulated genes identified by microarray analysis
Gene accession
number Gene name
Expression
ratio
Extracelluar matrix-related
genes
NM_004994 Matrix metalloproteinase 9 (gelatinase B, 92 kDa gelatinase, 92 kD
type IV collagenase)
0.20
NM_002427 Matrix metalloproteinase 13 (collagenase 3) 0.36
NM_003247 Thrombospondin 2 0.37
NM_002345 Lumican 0.43
U16306 Chondroitin sulfate proteoglycan 2 (versican) 0.59
NM_002290 Laminin, alpha 4 0.63
X02761 Fibronectin 1 0.84
NM_002428 Matrix metalloproteinase 15 (membrane-inserted) 1.73
NM_002160 Tenascin-C 3.24
Immune response-related
genes
NM_006152 Lymphoid-restricted membrane protein 0.17
NM_005601 Natural killer cell group 7 sequence 0.27
NM_002209 Integrin, alpha L (antigen CD11A (p180), lymphocyte function-
associated antigen 1; alpha polypeptide)
0.28
NM_001771 CD22 antigen 0.30
NM_000576 Interleukin 1, beta 0.36
NM_004931 CD8 antigen, beta polypeptide 1 (p37) 0.36
L36531 Integrin, alpha 8 0.40
X68742 Integrin, alpha 1 0.41
Y14737 Immunoglobulin heavy constant gamma 3 (G3m marker) 0.46
NM_001773 CD34 antigen 0.50
NM_006889 CD86 antigen (CD28 antigen ligand 2, B7-2 antigen) 0.55
NM_001769 CD9 antigen (p24) 1.96
NM_005356 Lymphocyte-specific protein tyrosine kinase 4.73
Cancer-related genes X16354 Carcinoembryonic antigen-related cell adhesion molecule 1
(biliary glycoprotein)
0.12
NM_000059 Breast cancer 2, early onset 0.22
NM_003810 Tumor necrosis factor (ligand) superfamily, member 10 0.25
NM_004619 TNF receptor-associated factor 5 0.39
NM_006910 retinoblastoma-binding protein 6 0.40
AF016266 Tumor necrosis factor receptor superfamily, member 10b 0.40
NM_000594 Tumor necrosis factor (TNF superfamily, member 2) 0.46
NM_004833 Absent in melanoma 2 0.47
NM_007295 Breast cancer 1, early onset 0.48
NM_005426 Tumor protein p53-binding protein, 2 0.51
NM_006850 Suppression of tumorigenicity 16 (melanoma differentiation) 0.54
NM_000043 Tumor necrosis factor receptor superfamily, member 6 0.55
NM_000575 Interleukin 1, alpha 0.56
Table 1 continued on following page
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in response to IL-13 (3.24-fold). However, transforming
growth factor (TGF)-b-related genes were not significantly
induced by IL-13 (TGF-b 1, 1.01-fold; TGF-b2, 0.34-fold;
TGF-b3, 0.41-fold; TGF-b receptor type II, 0.62-fold; TGF-b
receptor type III, 0.78-fold). This result suggested that TGF-b
was not involved in the increase in the expression of the TN-C
gene induced by IL-13.
TN-C expression in human dermal fibroblasts is upregulated by
IL-13
Subsequently, we investigated the effects of IL-13 on the
expression of TN-C in human dermal fibroblasts. First, we
investigated the effects of various cytokines (IL-13, IL-4, TGF-b,
and Oncostatin M; 10 ng/ml) on TN-C protein expression by
dermal fibroblasts. Two polypeptides (320 and 220 kDa),
corresponding to the two isoforms of TN-C, were detected in
the conditioned medium. IL-13 induced TN-C expression
modestly, whereas IL-4 had the strongest effect on TN-C protein
expression (Figure 1a). The effect of TGF-b and Oncostatin M
on TN-C expression was weaker than that of IL-13.
To determine whether the IL-13-mediated induction of
TN-C protein expression was correlated with an increase of
the mRNA level, mRNA expression was analyzed by North-
ern blotting. The TN-C mRNA level rose after stimulation
with IL-13 for 3 hours, and peaked (3.90-fold) after 12 hours
in comparison with the control level (Figure 1b). Thus, the
Table 1. continued
Gene accession
number Gene name
Expression
ratio
NM_000584 Interleukin 8 0.56
NM_005657 Tumor protein p53-binding protein, 1 0.61
NM_005610 Retinoblastoma-binding protein 4 0.62
NM_004620 TNF receptor-associated factor 6 0.67
NM_002892 Retinoblastoma-binding protein 1 2.10
NM_007115 Tumor necrosis factor, alpha-induced protein 6 61.15
Transforming growth
factor-b-related Genes
NM_000660 Transforming growth factor-b1 1.01
NM_003238 Transforming growth factor-b2 0.34
NM_003239 Transforming growth factor-b3 0.42
NM_003243 Transforming growth factor-b receptor III 0.78
D50683 Transforming growth factor-b receptor II 0.62
Others NM_000372 Tyrosinase (oculocutaneous albinism IA) 0.26
NM_002274 Keratin 13 0.26
NM_005922 Mitogen-activated protein kinase kinase kinase 4 0.32
NM_001992 Coagulation factor II (thrombin) receptor 0.34
NM_003238 Transforming growth factor, beta 2 0.34
X07695 Keratin 4 0.37
NM_002753 Mitogen-activated protein kinase 10 0.38
NM_003239 Transforming growth factor, beta 3 0.42
NM_001723 Bullous pemphigoid antigen 1 (230/240 kDa) 0.44
NM_004360 Cadherin 1, type 1, E-cadherin (epithelial) 0.45
NM_006282 Serine/threonine kinase 4 0.52
NM_006564 G protein-coupled receptor 0.53
NM_006121 Keratin 1 (epidermolytic hyperkeratosis) 0.53
D50683 Transforming growth factor, beta receptor II (70-80 kDa) 0.62
AB023420 Heat shock 70 kDa protein 4 0.63
NM_001793 Cadherin 3, type 1, P-cadherin (placental) 0.65
NM_004506 Heat shock transcription factor 2 0.66
AF005392 Tubulin, alpha 2 1.57
NM_000125 Estrogen receptor 1 1.87
NM_000376 Vitamin D (1,25- dihydroxyvitamin D3) receptor 1.92
X73502 Cytokeratin 20 1.93
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effect of IL-13 on the TN-C protein level paralleled but was
delayed relative to that on the mRNA level.
Mechanisms of IL-13-mediated TN-C upregulation
We determined whether the increase in TN-C mRNA levels
after IL-13 treatment involves transcriptional activation.
Actinomycin D completely blocked the IL-13-mediated
increase in TN-C mRNA, suggesting that IL-13’s stimulation
of TN-C mRNA involves direct activation of the transcription
of the TN-C gene and/or other genes involved in regulating
the TN-C gene (Figure 2a). Cycloheximide, an inhibitor of
protein synthesis, superinduced TN-C mRNA expression in
IL-13-treated fibroblasts, suggesting that repressor protein(s)
regulate transcription of the TN-C gene in human fibroblasts
and IL-13-mediated upregulation of TN-C expression is
independent of new protein synthesis.
In addition, we wished to determine whether IL-13
increased the stability of TN-C mRNA. Following the
inhibition of transcription by actinomycin D, the loss of
IL-13-induced TN-C mRNA expression was not significantly
different from that observed in the untreated cells (Figure 2b).
The failure of IL-13 to increase the half-life of TN-C mRNA
suggests that the IL-13-mediated induction of TN-C expres-
sion is regulated at the level of transcription. In fact, direct
measurement of the specific gene transcription using the
nuclear run-on transcription analysis revealed an elevation in
the rate of TN-C gene transcription in fibroblasts treated with
IL-13 (3.85-fold) (Figure 2c). Thus, we examined the effect of
IL-13 on the promoter activity of the human TN-C gene by
transient transfection. IL-13 stimulated the promoter activity
of TN-C (2.28-fold) (Figure 2d).
Wortmannin, LY294002, or Calphostin C inhibits IL-13-
mediated upregulation of TN-C protein and mRNA expression
We investigated which signaling pathways are involved in
the IL-13-mediated TN-C protein or mRNA induction.
Pretreatment of cells with phosphoinositide 3-kinase (PI3K)
inhibitors, wortmannin and LY294002, or an inhibitor of
classical and novel protein kinase C (PKC) isoforms and
phospholipase D, Calphostin C, blocked the IL-13-mediated
upregulation of TN-C protein expression (Figure 3a). These
inhibitors also blocked the IL-13-mediated upregulation
of TN-C mRNA expression, whereas rapamycin did not
(Figure 3b). However, they did not affect the expression
of glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
mRNA, demonstrating that at the indicated concentration,
these inhibitors did not have generalized toxic effects. These
results suggest that the PI3K, PKC, or phospholipase D
signaling pathway is essential for the IL-13-mediated expres-
sion of TN-C.
PI3K/Akt signaling pathway is activated following IL-13 treat-
ment, and wortmannin, LY294002, and Akt inhibitor reduce
this induction by IL-13
To confirm the involvement of the PI3K/Akt signaling
pathway in the IL-13-mediated expression of TN-C, we
determined whether the forced overexpression of a domi-
nant-negative mutant of Akt could overcome or inhibit the
effect of IL-13. Immunoblotting revealed that IL-13-induced
TN-C expression was downregulated by the transfection of
the dominant-negative mutant of Akt (Figure 4a).
Next, we investigated whether IL-13 actually activated
the PI3K/Akt signaling pathway. PI3K is composed of the
catalytic subunit p110 and the regulatory subunit p85. The
activity of PI3K is regulated through tyrosine phosphorylation
of p85. Immunoprecipitation using anti-PI3K p85 antibodies
revealed significant phosphorylation of p85 after 5–30 min-
utes of treatment with IL-13, followed by a slow decrease in
the cellular level of phosphorylated p85 (Figure 4b). Also,
immunoblotting using anti-phospho-Akt (Ser 473) antibody
revealed significant phosphorylation (3.27-fold) of Akt after
15 minutes of treatment with IL-13 (Figure 4c). Immunoblot-
ting for total Akt protein demonstrated that the amount of Akt
did not change in the presence of IL-13.
Furthermore, the Akt kinase assay showed that the level of
phosphorylated glycogen synthase kinase-3b was maximal
after 15 minutes (3.03-fold) of incubation with IL-13 (Figure
4d). Moreover, cells were pretreated with wortmannin,
LY294002, or a selective inhibitor of Akt, Akt inhibitor, for
1 h before stimulation with IL-13, and then the Akt kinase
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Figure 1. Induction of tenascin-C (TN-C) expression in human fibroblasts by
IL-13. (a) Cultured fibroblasts were stimulated with the indicated cytokines for
24 or 72 hours. Conditioned media and cell lysates (normalized for protein
concentrations as measured with the Bio-Rad reagent) were subjected to
immunoblotting with TN-C antibody and anti-b-actin antibody, respectively.
OM: Oncostatin M. (b) Cultured fibroblasts were incubated in the presence or
absence of 10 ng/ml of IL-13 with the indicated time courses, and Northern
blot analysis of TN-C mRNA expression was performed. Levels of
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA are shown as a
loading control. One experiment representative of three independent
experiments is shown. TN-C mRNA levels quantitated by scanning
densitometry and corrected for the levels of GAPDH in the same samples are
shown relative to the level in untreated cells (1.0) (lower panel). Data are
expressed as the mean7standard deviation of three independent
experiments. *Po0.05 as compared with the value in untreated cells.
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assay was performed. Wortmannin (100 nM), LY294002
(30 mM), or Akt inhibitor (20 mM) significantly inhibited the
Akt-induced phosphorylation of glycogen synthase kinase-3b,
whereas rapamycin (10 mM) did not (Figure 4e). These results
suggest that the treatment with IL-13 results in the activation
of the PI3K/Akt signaling pathway in human dermal
fibroblasts and that wortmannin, LY294002, or Akt inhibitor
inhibits the expression of TN-C in human dermal fibroblasts
stimulated by IL-13.
Activation of PKC in IL-13-stimulated fibroblasts
We investigated whether the activation of PKC is involved in
the IL-13-mediated production of TN-C protein and which
isozyme of PKC is activated by IL-13.
Pretreatment of cells with the selective PKC-d inhibitor
Rottlerin (Gschwendt et al., 1994) blocked the IL-13-mediated
upregulation of TN-C protein expression (Figure 5a), whereas
the selective PKC-a inhibitor Go¨6976 (Martiny-Baron et al.,
1993) did not. Furthermore, the overexpression of dominant-
negative PKCs had no significant effect on TN-C protein
expression in the absence of IL-13, whereas IL-13’s effect on
TN-C protein was abrogated by the dominant-negative PKC-d
as well as -e (Figure 5b). These results suggest that IL-13
regulates the expression of TN-C protein through PKC
signaling, especially PKC-d and -e, in human dermal fibroblasts.
It is generally accepted that inactive PKC isoforms are
located in the nucleus or cytoplasm, and translocated to the
plasma membrane and/or cytoskeleton after activation
(Mochly-Rosen et al., 1990; Tourkina et al., 2001). Next, to
examine the activation of PKC-a, -d, and -e by IL-13,
immunofluorescence microscopy using anti-PKC-a, -d, and
-e antibodies was performed. The result revealed that only
PKC-d and -e were translocated to the plasma membrane in
IL-13-treated fibroblasts (Figure 5c).
DISCUSSION
TN-C is a polymorphic high-molecular mass extracellular
matrix glycoprotein composed of six similar subunits joined
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Figure 2. Effects of actinomycin D or cycloheximide on IL-13-mediated increase in tenascin-C (TN-C). (a) Human dermal fibroblasts were serum-starved for
24 hours and incubated in the absence or presence of 2.5 mg/ml of actinomycin D or 10 mg/ml of cycloheximide, with or without 10 ng/ml of IL-13, for 12 hours.
Northern blot analysis of TN-C mRNA expression was performed. TN-C mRNA levels quantitated by scanning densitometry and corrected for the levels of
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in the same samples are shown relative to the level in untreated cells (1.0) (lower panel). *Po0.05 as
compared with the value in untreated cells. AcD; actinomycin D, CHX; cycloheximide. (b) Effect of IL-13 on the half-life of TN-C mRNA was examined. Human
dermal fibroblasts were serum-starved for 24 hours and incubated in the absence or presence of 10 ng/ml of IL-13 for 12 hours before the addition of 2.5 mg/ml of
actinomycin D. mRNA was extracted from the cells at the indicated time points after actinomycin D was administrated. Northern blot analysis of TN-C mRNA
expression was performed. The corrected density by GAPDH was expressed as a percentage of the value at time 0 and plotted on a scale. The solid line indicates
levels in IL-13-treated cells, and the dotted line indicates control (untreated) levels. Statistical analysis was performed comparing the value of each time point
with the Mann–Whitney U-test. (c) Dermal fibroblasts were serum-starved for 24 hours and treated with 10 ng/ml of IL-13 for 12 hours. Nuclei were prepared as
described in ‘‘Materials and Methods’’. GAPDH is a positive control, and the corresponding vector is a negative control. One experiment representative of three
independent experiments is shown. The TN-C gene transcription levels quantitated by scanning densitometry and corrected for the levels of GAPDH
transcription in the same samples are shown relative to the level in untreated cells (1.0). (d) The plasmid carrying a 2.1 kb fragment of the human TN-C
promoter was used in the transient transfection in the presence or absence of IL-13. The number shows the promoter activity stimulated by IL-13 relative to the
promoter activity without IL-13, which was set at 1. The means7standard deviation of four independent experiments are shown. *Po0.05 as compared with the
value in untreated cells.
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together at their NH2 terminus by disulfide bonds (Erickson,
1993). Although its exact biological functions are still
unknown, TN-C has been shown to inhibit cell adhesion to
fibronectin and included among ‘‘antiadhesive molecules’’,
which seem to play roles in the processes of morphogenesis,
wound healing, and cancer progression (Borsi et al., 1994).
It is known that the expression of TN-C is increased under
fibrotic conditions such as scarring (Harty et al., 2003).
Upregulation of TN-C expression is also observed in the
dermis or lungs of patients with systemic sclerosis, an
autoimmune disorder characterized by the excessive deposi-
tion of extracellular matrix components in the skin and
internal organs (Rodnan et al., 1979; LeRoy, 1992; Tourkina
et al., 2001). On the other hand, IL-13 has also been
implicated in the pathogenesis of fibrotic disease in several
organs (Lee et al., 2001). We previously reported that IL-13
induced the expression of type I collagen to the same extent
as IL-4 (Jinnin et al., 2004b). Previous studies showed that IL-
13 induced hepatic or pulmonary fibrosis in mice in vivo
(Chiaramonte et al., 1999; Zhu et al., 1999). In addition,
Kolodsick et al. (2004) reported that IL-13-deficient mice
were protected from fluorescein isothiocyanate-induced
fibrosis of the lung because of impaired collagen synthesis
by fibroblasts, whereas IL-4-deficient mice were not pro-
tected. IL-13 may play more important roles in the regulation
of fibrosis in vivo than IL-4. It was reported that serum levels
of IL-13 increased reflecting systemic inflammation in
patients with systemic sclerosis (Hasegawa et al., 1997).
Furthermore, the amount of IL-13 protein was shown to be
increased in the culture supernatants of alveolar macro-
phages from systemic sclerosis patients compared to control
subjects (Hancock et al., 1998). These findings suggest that
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Figure 3. Effects of wortmannin, LY294002, and Calphostin C on IL-13-induced tenascin-C (TN-C) expression. (a) Human dermal fibroblasts were serum-
starved for 24 hours and pre-treated with 50 or 100 nM wortmannin, 10 or 30 mM LY294002, or 100 or 200 nM Calphostin C, for 1 h before the addition of
10 ng/ml of IL-13 for 72 hours. Conditioned media and cell lysates (normalized for protein concentrations as measured with the Bio-Rad reagent) were subjected
to immunoblotting with TN-C antibody (conditioned media) and anti-b-actin antibody (cell lysates), respectively. One experiment representative of three
independent experiments is shown. The levels of TN-C quantitated by scanning densitometry and corrected for the levels of b-actin are shown relative to the
level in untreated (1.0). *Po0.05 as compared with the value in untreated cells. Wo; wortmannin, LY: LY294002. (b) A Northern blot analysis of TN-C mRNA
expression was performed. Wortmannin (100 nM), LY294002 (30 mM), Calphostin C (200 nM), and rapamycin (10 mM) were added 1 h before the addition of
10 ng/ml of IL-13. After 24 h, cells were collected. One experiment representative of three independent experiments is shown. TN-C mRNA levels quantitated
by scanning densitometry and corrected for the levels of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in the same samples are shown relative to the
level in untreated cells (1.0) (lower panel). *Po0.05 as compared with the value in IL-13-treated cells without inhibitors.
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TN-C expression is upregulated in systemic sclerosis due to
IL-13 signaling, and that blockade of the PI3K or PKC
signaling pathway may also have therapeutic value by
reducing the amount of TN-C produced during fibrosis.
Makhluf et al. (1996) indicated that an IL-4-induced
increase in TN-C mRNA was controlled at the level of
transcription. IL-13 shares many biological properties with
IL-4 as described above, and in the present study, we
obtained similar results using IL-13. In addition, we showed
that IL-13 induced the transcription of the TN-C gene.
PI3K/Akt is activated in response to a variety of stimuli,
including growth factors and cytokines (Hemmings, 1997).
Our results showed that treatment with PI3K inhibitors,
wortmannin, and LY294002 blocked the IL-13-mediated
upregulation of TN-C protein and mRNA expression, whereas
treatment with rapamycin did not. This suggested that the
mammalian target of rapamycin is not involved in the effect
of IL-13 on TN-C expression, and that other downstream
signaling cascades including glycogen synthase kinase-3 may
mediate the upregulation of TN-C expression by IL-13.
The PKC family of proteins is comprised of at least 10
isozymes with diverse functions that are involved in numerous
important cellular processes (Jimenez et al., 2001). Studies
have established that the activation of PKC is necessary for the
stimulation of gene expression in response to various cytokines,
and that several celluar responses to IL-13 are regulated by a
PKC-dependent signal transduction pathway. For example,
PKC-d and -z mediate IL-4/IL-13-induced germline e transcrip-
tion in human B cells (Ikizawa et al., 2001). In addition,
Tourkina et al. (2001) reported that thrombin stimulated TN-C
expression via opposing PKC-e signaling mechanisms in
systemic sclerosis and normal lung fibroblasts. Thus, the PKC
TN-C
-Actin
IL-13
IL-13 (minutes)
IL-13 (minutes)
IL-13 (minutes)
Vector
DN Akt
– –
–
– –
–
+
++
+
+
+
5 4
3
2
1
4
3
2
1
3
2
1
R
el
at
ive
de
ns
ito
m
et
ric
u
n
it
R
el
at
ive
de
ns
ito
m
et
ric
u
n
it
R
el
at
ive
de
ns
ito
m
et
ric
u
n
it
Phospho-Akt
Total-Akt
Phospho-p85
Phospho-GSK-3
Phospho-GSK-3Total-p85
0 5 15 30 60
0
0 0 0 0 0 0
5 15
15 15 15 15 15 15
30 60
IL-13 (minutes) 0 5 15 30 60
Wortmannin
LY294002
Rapamycin
Akt inhibitor
Vehicle
–
–
–
–
–
+
–
–
–
–
–
+
–
–
–
–
–
+
–
–
–
–
–
+
–
–
–
–
–
+
–
–
–
–
–
+
–
–
–
–
–
+
–
–
–
–
–
+
–
–
–
–
–
+
–
–
–
–
–
+
*
**
*
*
*
a
b
c
d
e
Figure 4. Activation of the phosphoinositide 3-kinase (PI3K)/Akt signaling pathway by IL-13 in human dermal fibroblasts. (a) For immunoblot analysis, the
overexpression of the dominant-negative mutant of Akt in human dermal fibroblasts was performed by electroporating as described in ‘‘Materials and Methods’’.
Twenty-four hours after the transfection, cells were treated with IL-13 (10 ng/ml) and then 24 hours later, lysed. The lysates were electrophoresed through a 10%
polyacrylamide gel, transferred to a nitrocellulose membrane, and probed with anti-tenascin-C (TN-C) antibody. The same membrane was then stripped and
reprobed with anti-b-actin antibody as a loading control. One experiment representative of three independent experiments is shown. The levels of TN-C
quantitated by scanning densitometry and corrected for the levels of b-actin in the same samples are shown relative to the level in untreated cells transfected
with vector (1.0) (lower panel). *Po0.05 as compared with the value in IL-13-treated cells transfected with empty vector. DN; dominant-negative. (b) Human
dermal fibroblasts were serum-starved for 24 hours and treated with 10 ng/ml of IL-13 for the periods indicated. Cell lysates were immunoprecipitated with
anti-p85 antibody, then immunoblotted with anti-phosphotyrosine (4G10) antibody. The same membrane was stripped and reprobed with anti-p85 antibody
to determine the abundance of total p85 protein. One experiment representative of three independent experiments is shown. The levels of phosphorylated p85
quantitated by scanning densitometry and corrected for the levels of total p85 in the same samples are shown relative to the level in untreated cells (1.0) (lower
panel). Data are expressed as the mean7standard deviation of three independent experiments. *Po0.05 as compared with the value in untreated cells. (c) Cell
lysates (30 mg of protein/sample) were subjected to immunoblotting with anti-phospho-Akt (Ser 473) antibodies. That the amounts of Akt proteins were
unchanged was confirmed by immunoblotting using anti-Akt antibodies. One experiment representative of three independent experiments is shown. The levels
of phosphorylated Akt quantitated by scanning densitometry and corrected for the levels of total Akt in the same samples are shown relative to the level in
untreated cells (1.0) (lower panel). (d) To determine the time course of Akt kinase activity, human dermal fibroblasts were serum-starved for 24 hours and treated
with 10 ng/ml of IL-13 for the period indicated. After the treatment, Akt was collected by immunoprecipitation, and subjected to an in vitro kinase assay in the
presence of glycogen synthase kinase-3b. The samples were subjected to immunoblotting with anti-phospho-glycogen synthase kinase-3b antibodies. (e) Cells
were also preincubated for 1 h with 100 nM wortmannin, 30 mM LY294002, 10 mM rapamycin, or 20mM Akt inhibitor and then stimulated for 0.25 hours with
10 ng/ml of IL-13, before a kinase assay was performed.
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family may be one of the main signaling pathways regulating
TN-C levels. However, there is a limitation with the
interpretation of our results. There are some reports that used
higher concentrations of Rottlerin or Go¨6976. Although the
dominant-negative data support our conclusion, the possible
involvement of another conventional PKC isoform, such as
PKC-b, will need to be examined. In addition, the roles of the
downstream signaling cascade of the PI3K/Akt or PKC signaling
pathway and of crosstalk between these pathways and other
signaling pathways in the IL-13-mediated induction of TN-C
expression also must be examined.
MATERIALS AND METHODS
Reagents
Wortmannin, LY294002, Akt inhibitor II, Calphostin C, Rottlerin,
and Go¨6976 were purchased from Calbiochem (La Jolla, CA).
Recombinant human IL-13 was obtained from R&D systems
(Minneapolis, MN). Actinomycin D and cycloheximide were
purchased from Sigma (St Louis, MO). Antibodies selective for Akt
and phospho-Akt (Ser473), and the Akt kinase assay kits were from
New England Biolabs (Beverly, MA). Anti-PI3K p85 antibodies and
anti-phosphotyrosine (4G10) antibodies were from Upstate Biotech-
nology (Lake Placid, NY). Anti-PKC-a, -d, or -e antibody was from
Santa Cruz Biotechnology (Santa Cruz, CA).
Cell cultures
Fibroblasts were obtained by skin biopsy from healthy donors. All
biopsies were obtained with institutional review board approval and
written informed consent according to the Declaration of Helsinki
Principles. Primary explant cultures were established in 25-cm2
culture flasks in modified Eagle’s medium supplemented with 10%
fetal calf serum, 2 mM glutamine, and 50 mg/ml gentamycin, as
described previously (Ihn et al., 1996, 1997). Monolayer cultures
were maintained at 371C in 5% CO2 in air. Fibroblasts between the
third and sixth subpassages were used for experiments.
Microarray
The cDNA microarray hybridization experiments were performed
using Intelligene Human Cancer CHIP Version 3.0 (codes X102)
(Takara, Tokyo, Japan) according to the manufacturer’s directions. The
protocol used and a complete listing of the nearly 630 genes related to
cancer on the Human Cancer CHIP are available on the Web. An
approximately 300-bp cDNA region of each gene, which has minimal
homology with other genes registered in the cDNA database, is
spotted on this DNA chip. Poly (A)þ mRNA was isolated and used
to prepare cDNAs that were fluorescently labeled with either Cy3
(IL-13-untreated) or Cy5 (IL-13-treated) fluorescent dye. Samples
were mixed and applied to DNA microarrays. The arrays were
scanned using ScanArray (GS Lumonics), and the data were analyzed
using Quant Array (BM BIO, Tokyo, Japan) (Hishikawa et al., 2001).
A gene expression ratio (Cy5/Cy3) 41.5 or o0.67 was considered
significant.
Immunoblotting
Human dermal fibroblasts were cultured until they were confluent,
then the media were collected. Aliquots of conditioned medium
(normalized for cell numbers) were subjected to immunoblotting
with an anti-human TN-C monoclonal antibody (NEC1b) (kindly
provided by Dr Wolfgang Rettig) (Rettig and Garin-Chesa, 1989)
(1:500 dilution) (Jinnin et al., 2004a).
For immunoblotting using antibodies against phospho-Akt, mem-
branes were incubated with anti-phospho-Akt (Ser473) monoclonal
antibody (1:1,000) overnight at 41C. As a loading control, immunoblot-
ting was also performed using antibodies against total Akt (1:1,000).
Preparation of RNA and Northern blot analysis
Total RNA was extracted using an acid guanidinium thiocyanate–-
phenol–chloroform method and analyzed by Northern blotting as
described previously (Ihn et al., 1997). The following cDNA probes
were used: a human TN-C 1431-bp EcoRI fragment (kindly provided
by Dr Mario Bourdon, La Jolla Institute for Experimental Medicine,
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Figure 5. Activation of protein kinase C (PKC) signaling pathway by IL-13. (a) Human dermal fibroblasts were serum-starved for 24 hours and pre-treated with 1
or 3 mM Rottlerin, or 50 or 100 nM Go¨6976, for 1 h before the addition of IL-13 (10 ng/ml) for 72 hours. Conditioned media and cell lysates (normalized for protein
concentrations as measured with the Bio-Rad reagent) were subjected to immunoblotting with tenascin-C (TN-C) antibody and anti-b-actin antibody,
respectively. One experiment representative of three independent experiments is shown. The levels of TN-C quantitated by scanning densitometry and corrected
for the levels of b-actin are shown relative to the level in untreated (1.0), as described in Figure 3a. (b) For immunoblot analysis, the overexpression of the
dominant-negative mutant of PKC-a, -d, or -e in human dermal fibroblasts was performed by electroporation as described in Figure 4a. DN; dominant negative.
WT; wild type. (c) The subcellular localization of endogenous PKC-a, -d, and -e was visualized by immunofluorescence microscopy. Dermal fibroblasts were
serum-starved for 24 hours and incubated in the presence or absence of IL-13 (10 ng/ml) for 1 hour.
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La Jolla, CA) and a GAPDH 437-bp HindIII–NotI fragment. The
membranes were then washed and exposed to X-ray film.
Nuclear run-on transcription
The nuclear run-on transcription analysis was performed according
to a modified protocol that uses digoxigenin-labeled uridine tripho-
sphate (Bentley and Groudine, 1986; Celano et al., 1989; Merscher
et al., 1994; Jinnin et al., 2004b).
Transient transfection
Fibroblasts were grown to 50% confluence in 100-mm dishes in
modified Eagle’s medium with 10% fetal calf serum. The media were
replaced with serum-free medium, and fibroblasts were transfected
with the TN-C promoter constructs driving chloramphenicol
acetyltransferase expression, employing FuGENE6 as described
previously (Ihn et al., 2002). In order to normalize for minor
variations in transfection efficiency, 1mg of pSV-b-galactosidase
vector (Promega, Madison, WI) was included in all transfections.
After 24 hours of incubation, cells were incubated for another
24 hours in the absence or presence of 10 ng/ml IL-13. Subsequently,
cells were harvested in 0.25 M Tris-HCl (pH 8) and fractured by
freeze–thawing. Extracts, normalized for protein concentrations as
measured with the Bio-Rad reagent, were incubated with butyl-CoA
and [14C]-chloramphenicol for 90 minutes at 371C. Butylated
chloramphenicol was extracted using an organic solvent (2:1
mixture of tetramethylpentadecane and xylene) and quantitated by
scintillation counting. The data were standardized based on
b-galactosidase activity. Each experiment was performed in duplicate.
For the immunoblot analysis using a dominant-negative mutant
of Akt, PKC-a, -d, or -e, a transient transfection was performed by
electroporating into human dermal fibroblasts, using a Bio-Rad Gene
Pulser apparatus. Cells (3 106) were resuspended in 500 ml of
phosphate-buffered saline containing 10mg of DNA and electro-
porated at 950mF and 300 V.
Immunoprecipitation
Phosphorylated levels of p85 were examined by immunoprecipita-
tion using antibody for p85 and phosphotyrosine (Yamane et al.,
2003). The same membrane was then stripped and reprobed with
anti-p85 antibody to show the total amount of p85.
Assay of Akt activation
The activation of Akt was examined using an Akt kinase assay kit
according to the manufacturer’s instructions (Yamane et al., 2003).
Plasmids
The dominant-negative mutant form of Akt was kindly provided by Dr
Brian A. Hemmings (Alessi et al., 1996; Andjelkovic et al., 1997). The
dominant-negative mutant forms of PKC-a, -d, and -e were obtained
from Dr Jae-Won Soh (Soh et al., 2001), Dr Weiqun Li (Li et al., 1996),
and Dr Alex Toker (Deaconess Medical Center, Boston, MA) (Berrier
et al., 2000), respectively. A full-length TN-C promoter construct (bp
þ 75 to 2100 relative to the transcription start site) linked to the
chloramphenicol acetyltransferase reporter gene (PTN-I-CAT) was
kindly provided by Dr Roberto Gherzi (Gherzi et al., 1995).
Plasmids used in the transient transfection assays were purified
twice on CsCl gradients, as described previously (Ihn et al., 1997). At
least two different plasmid preparations were used for each experiment.
Immunofluorescence microscopy
Dermal fibroblasts were grown in four-well LAK TEK chambers
(Nunc, Naperville, IL) to subconfluence as described above. After
24 hours of serum starvation, cells were fixed with 3.7% formalde-
hyde, permeabilized with 0.5% Triton X-100 in phosphate buffered
saline, and blocked with 10% fetal calf serum in Triton X-100 in
phosphate buffered saline. Cells were stained with anti-PKC-a, -d, or
-e antibodies as the primary antibody, washed, and incubated with
FITC-conjugated secondary antibodies. To visualize the antibody
staining, Zeiss fluorescent microscope was used (Asano et al., 2004).
For the positive control of PKC-a, -d, and -e, we also examined the
cells stimulated with phorbol myristic acetate, an activator of PKC
(data not shown) (Li et al., 2002; Runyan et al., 2003).
Statistical analysis
Data presented as bar graphs are the means7standard deviation of
at least three independent experiments. Statistical analysis was
performed using the Mann–Whitney U-test (Po0.05 was considered
significant).
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
This study was supported in part by a grant for scientific research from the
Japanese Ministry of Education, Science, Sports and Culture, by project
research for progressive systemic sclerosis from the Japanese Ministry of
Health and Welfare. We thank Dr Wolfgang Rettig, Dr Mario Bourdon, Dr
Brian A. Hemmings, Dr Jae-Won Soh, Dr Weiqun Li, Dr Alex Toker, and Dr
Roberto Gherzi for kindly providing NEC1b, the human TN-C 1431-bp
fragment, the dominant-negative mutant form of Akt, the dominant-negative
mutant form of PKC-a, the dominant-negative mutant of PKC-d, the dominant-
negative form of PKC-e and the PTN-I-CAT construct, respectively.
The protocol used and a complete listing of the nearly 630 genes on Human
Cancer CHIP Version 3.0 (Takara, Tokyo, Japan) are available at http://
bio.takara.co.jp/BIO_EN/catalog_d.asp?C_ID=C1145.
REFERENCES
Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P et al.
(1996) Mechanism of activation of protein kinase B by insulin and IGF-1.
EMBO J 15:6541–51
Andjelkovic M, Alessi DR, Meier R, Fernandez A, Lamb NJ, Frech M et al.
(1997) Role of translocation in the activation and function of protein
kinase B. J Biol Chem 272:31515–24
Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K (2004) Impaired Smad7-Smurf-
mediated negative regulation of TGF-b signaling in scleroderma
fibroblasts. J Clin Invest 113:253–64
Bentley D, Groudine M (1986) A block to elongation is largely responsible for
decreased transcription of c-myc in differentiated HL60 cells. Nature
321:702–6
Berrier AL, Mastrangelo AM, Downward J, Ginsberg M, LaFlamme SE (2000)
Activated R-ras, Rac1, PI 3-kinase and PKCe can each restore cell
spreading inhibited by isolated integrin b1 cytoplasmic domains. J Cell
Biol 151:1549–60
Borsi L, Balza E, Castellani P, Carnemolla B, Ponassi M, Querze G et al.
(1994) Cell-cycle dependent alternative splicing of the tenascin primary
transcript. Cell Adhes Commun 1:307–17
Celano P, Berchthold C, Casero Jr RA (1989) A simplification of the nuclear
run-off transcription assay. BioTechniques 7:942–4
Chiaramonte MG, Donaldson DD, Cheever AW, Wynn TA (1999) An
IL-13 inhibitor blocks the development of hepatic fibrosis during a T-
helper type 2-dominated inflammatory response. J Clin Invest 104:
777–85
www.jidonline.org 559
M Jinnin et al.
IL-13 Induces TN-C
Erickson HP (1993) Tenascin-C, tenascin-R and tenascin-X: a family of
talented proteins in search of functions. Curr Opin Cell Biol 5:869–76
Gherzi R, Carnemolla B, Siri A, Ponassi M, Balza E, Zardi L (1995) Human
tenascin gene. Structure of the 50-region, identification, and character-
ization of the transcription regulatory sequences. J Biol Chem 270:
3429–34
Gschwendt M, Muller HJ, Kielbassa K, Zang R, Kittstein W, Rincke G et al.
(1994) Rottlerin, a novel protein kinase inhibitor. Biochem Biophys Res
Commun 199:93–8
Hancock A, Armstrong L, Gama R, Millar A (1998) Production of interleukin
13 by alveolar macrophages from normal and fibrotic lung. Am J Respir
Cell Mol Biol 18:60–5
Harty M, Neff AW, King MW, Mescher AL (2003) Regeneration or scarring: an
immunologic perspective. Dev Dyn 226:268–79
Hasegawa M, Fujimoto M, Kikuchi K, Takehara K (1997) Elevated serum
levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic
sclerosis. J Rheumatol 24:328–32
Hemmings BA (1997) Akt signaling: linking membrane events to life and
death decisions. Science 275:628–30
Hishikawa K, Oemar BS, Nakaki T (2001) Static pressure regulates connective
tissue growth factor expression in human mesangial cells. J Biol Chem
276:16797–803
Ihn H, LeRoy EC, Trojanowska M (1997) Oncostatin M stimulates transcrip-
tion of the human a2(I) collagen gene via the Sp1/Sp3-binding site. J Biol
Chem 272:24666–72
Ihn H, Ohnishi K, Tamaki T, LeRoy EC, Trojanowska M (1996) Transcriptional
regulation of the human a2(I) collagen gene. Combined action of
upstream stimulatory and inhibitory cis-acting elements. J Biol Chem
271:26717–23
Ihn H, Yamane K, Asano Y, Kubo M, Tamaki K (2002) IL-4 up-regulates the
expression of tissue inhibitor of metalloproteinase-2 in dermal fibroblasts
via the p38 mitogen-activated protein kinase dependent pathway.
J Immunol 168:1895–902
Ikizawa K, Kajiwara K, Izuhara K, Yanagihara Y (2001) PKCd and z mediate
IL-4/IL-13-induced germline e transcription in human B cells: a putative
regulation via PU.1 phosphorylation. Biochem Biophys Res Commun
288:34–41
Jimenez SA, Gaidarova S, Saitta B, Sandorfi N, Herrich DJ, Rosenbloom JC
et al. (2001) Role of protein kinase C-d in the regulation of collagen gene
expression in scleroderma fibroblasts. J Clin Invest 108:1395–403
Jinnin M, Ihn H, Asano Y, Yamane K, Trojanowska M, Tamaki K (2004a)
Tenascin-C upregulation by transforming growth factor-b in human
dermal fibroblasts involves Smad3, Sp1, and Ets1. Oncogene 23:
1656–67
Jinnin M, Ihn H, Yamane K, Tamaki K (2004b) Interleukin-13 stimulates the
transcription of the human a2(I) collagen gene in human dermal
fibroblasts. J Biol Chem 279:41783–91
Kolodsick JE, Toews GB, Jakubzick C, Hogaboam C, Moore TA, McKenzie A
et al. (2004) Protection from fluorescein isothiocyanate-induced fibrosis
in IL-13-deficient, but not IL-4-deficient, mice results from impaired
collagen synthesis by fibroblasts. J Immunol 172:4068–76
Lee CG, Homer RJ, Zhu Z, Lanone S, Wang X, Koteliansky V et al. (2001)
Interleukin-13 induces tissue fibrosis by selectively stimulating and
activating transforming growth factor b(1). J Exp Med 194:809–21
LeRoy EC (1992) A brief overview of the pathogenesis of scleroderma
(systemic sclerosis). Ann Rheum Dis 51:3412–9
Li J, Hellmich MR, Greeley Jr GH, Townsend Jr CM, Evers BM (2002)
Phorbol ester-mediated neurotensin secretion is dependent on the
PKC-a and -d isoforms. Am J Physiol Gastrointest Liver Physiol 283:
1197–206
Li W, Michieli P, Alimandi M, Lorenzi MV, Wu Y, Wang LH et al. (1996)
Expression of an ATP binding mutant of PKC-d inhibits Sis-induced
transformation of NIH3T3 cells. Oncogene 15:731–7
Makhluf HA, Stepniakowska J, Hoffman S, Smith E, LeRoy EC, Trojanowska M
(1996) IL-4 upregulates tenascin synthesis in scleroderma and healthy
skin fibroblasts. J Invest Dermatol 107:856–9
Martiny-Baron G, Kazanietz MG, Mischak H, Blumberg PM, Kochs G, Hug H
et al. (1993) Selective inhibition of protein kinase C isozymes by the
indolocarbazole Go¨ 6976. J Biol Chem 268:9194–7
McKenzie ANJ, Culpepper JA, de Malefyt R, Briere F, Punnonen J, Aversa G
et al. (1993) Interleukin 13, a T-cell-derived cytokine that regulates
human monocyte and B-cell function. Proc Natl Acad Sci USA
90:3735–9
Merscher S, Hanselmann R, Welter C, Dooley S (1994) Nuclear runoff
transcription analysis using chemiluminescent detection. Biotechniques
16:1024–6
Minty A, Chalon P, Derocq JM, Dumont X, Guillemot JC, Kaghad M et al.
(1993) Interleukin-13 is a new human lymphokine regulating inflamma-
tory and immune responses. Nature 362:248–50
Mochly-Rosen D, Henrich CJ, Cheever L, Khaner H, Simpson PC (1990) A
protein kinase C isozyme is translocated to cytoskeletal elements on
activation. Cell Regul 1:693–706
Morgan JG, Dolganov GM, Robbins SE, Hinton LM, Lovett M (1992) The
selective isolation of novel cDNAs encoded by the regions surrounding
the human interleukin 4 and 5 genes. Nucleic Acids Res 20:5173–9
Oriente A, Fedarko NS, Pacocha SE, Huang SK, Lichtenstein LM, Essayan DM
(2000) Interleukin-13 modulates collagen homeostasis in human skin
and keloid fibroblasts. J Pharmacol Exp Ther 292:988–94
Punnonen J, Aversa G, Cocks BG, McKenzie AN, Menon S, Zurawski G et al.
(1993) Interleukin 13 induces interleukin 4-independent IgG4 and IgE
synthesis and CD23 expression by human B cells. Proc Natl Acad Sci
USA 90:3730–4
Rettig WJ, Garin-Chesa P (1989) Cell type-specific control of human
neuronectin secretion by polypeptide mediators and phorbol ester.
J Histochem Cytochem 37:1777–86
Rodnan GP, Lipinski E, Luksick J (1979) Skin thickness and collagen content
in progressive systemic sclerosis and localized scleroderma. Arthritis
Rheum 22:130–40
Runyan CE, Schnaper HW, Poncelet AC (2003) Smad3 and PKCd mediate
TGF-b1-induced collagen I expression in human mesangial cells. Am J
Physiol Renal Physiol 285:413–22
Soh JW, Mao Y, Liu L, Thompson WJ, Pamukcu R, Weinstein IB (2001) Protein
kinase G activates the JNK1 pathway via phosphorylation of MEKK1. J
Biol Chem 276:16406–10
Tourkina E, Hoffman S, Fenton JW, Lipsitz S, Silver RM, Ludwicka-Bradley A
(2001) Depletion of protein kinase C e in normal and scleroderma lung
fibroblasts has opposite effects on tenascin expression. Arthritis Rheum
44:1370–81
Yamane K, Ihn H, Tamaki K (2003) Epidermal growth factor up-regulates
expression of transforming growth factor b receptor type II in human
dermal fibroblasts by phosphoinositide 3-kinase/Akt signaling pathway:
Resistance to epidermal growth factor stimulation in scleroderma
fibroblasts. Arthritis Rheum 48:1652–66
Yoshidome H, Kato A, Miyazaki M, Edwards MJ, Lentsch AB (1999) IL-13
activates STAT6 and inhibits liver injury induced by ischemia/reperfu-
sion. Am J Pathol 155:1059–64
Zhu Z, Homer RJ, Wang Z, Chen Q, Geba GP, Wang J et al. (1999) Pulmonary
expression of interleukin-13 causes inflammation, mucus hypersecre-
tion, subepithelial fibrosis, physiologic abnormalities, and eotaxin
production. J Clin Invest 103:779–88
Zurawski G, de Vries JE (1994) Interleukin 13, an interleukin 4-like cytokine
that acts on monocytes and B cells, but not on T cells. Immunol Today
15:19–26
Zurawski SM, Vega FJ, Huyghe B, Zurawski G (1993) Receptors for
interleukin-13 and interleukin-4 are complex and share a novel
component that functions in signal transduction. EMBO J 12:2663–70
560 Journal of Investigative Dermatology (2006), Volume 126
M Jinnin et al.
IL-13 Induces TN-C
